Background: The role of radical prostatectomy (RP) is still controversial for locally advanced prostate cancer (PC). Radiotherapy (RT) and hormonal therapy (HT) are usually used as a primary treatment. Material and Methods: A systematic online search was conducted according to Preferred Reporting Items for Systematic Review and Meta-Analysis statement. Eligible publications reporting the overall survival (OS) and/or disease-specific survival (DSS) were included. A total of 14 studies, including 17,869 patients, were considered for analysis. The impact of therapeutic modalities on survival was assessed, with a risk of bias assessment according to the Newcastle Ottawa Scale. Results: For RP, RT, and HT, the mean 10-year OS was 70.7% (95% CI 61.3-80.2), 65.8% (95% CI 48.1-83.3), and 22.6% (95% CI 4.9-40.3; p = 0.001), respectively. The corresponding 10-year DSS was 84.1% (95% CI 75.1-93.2), 89.4% (95% CI 70.1-108.6), and 50.4% (95% CI 31.2-69.6; p = 0.0127), respectively. Among all treatment combinations, RP displayed significant improvement in OS when included in the treatment (Z = 4.01; p < 0.001). Adjuvant RT significantly improved DSS (Z = 2.7; p = 0.007). Combination of RT and HT favored better OS in comparison to monotherapy with RT or HT (Z = 3.61; p < 0.001). Conclusion: Improved outcomes in advanced PC were detected for RP plus adjuvant RT vs. RP alone and RT plus adjuvant HT vs. RT alone with comparable survival results between both regimens. RP with adjuvant RT may present the modality of choice when HT is contraindicated.

Keywords:
Advanced prostate cancer, Anti-hormonal therapy , Lymph-node positive, Prostate cancer, Radical prostatectomy, Radiotherapy
1.
Wallis CJ, Saskin R, Choo R, et al: Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol 2016;70:21-30.
2.
Mason MD, Parulekar WR, Sydes MR, et al: Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 2015;33:2143-2150.
3.
Yamamoto S, Kawakami S, Yonese J, et al: Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution. Int J Clin Oncol 2014;19:1085-1091.
4.
Mottet N, Bellmunt J, Briers E, et al: EAU Guideline on Prostate Cancer, 2015.
5.
Gakis G, Boorjian SA, Briganti A, et al: The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol 2014;66:191-199.
6.
Moher D, Shamseer L, Clarke M, et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
7.
Wells GA, Shea B, O'Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
8.
Gandaglia G, Sun M, Trinh QD, et al: Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis. BJU Int 2014;114:E62-E69.
9.
Saito T, Kitamura Y, Komatsubara S, Matsumoto Y, Sugita T, Hara N: Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan. Asian J Androl 2006;8:555-561.
10.
Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA: Radical prostatectomy for clinical T4 prostate cancer. Cancer 2006;106:2603-2609.
11.
Messing EM, Manola J, Yao J, et al: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-479.
12.
Gandaglia G, Karakiewicz PI, Briganti A, et al: Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol 2015;22:89-95.
13.
Moschini M, Fossati N, Abdollah F, et al: Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. Prostate Cancer Prostatic Dis 2016;19:63-67.
14.
Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE: Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008;54:344-352.
15.
Engel J, Bastian PJ, Baur H, et al: Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010;57:754-761.
16.
Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H: Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161:1223-1227.
17.
Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ: 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int 2012;110:1709-1713.
18.
Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group: Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 2010;105:1074-1081.
19.
Fosså SD, Wiklund F, Klepp O, et al: Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7. Eur Urol 2016;70:684-691.
20.
Souhami L, Bae K, Pilepich M, Sandler H: Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 2009;27:2137-2143.
21.
Porcaro AB, De Luyk N, Corsi P, et al: Clinical factors predicting bilateral lymph node invasion in high-risk prostate cancer. Urol Int 2017, Epub ahead of print.
22.
Hodgson D, Warde P, Gospodarowicz M: The management of locally advanced prostate cancer. Urol Oncol 1998;4:3-12.
23.
Fallon B, Williams RD: Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am 1990;17:853-866.
24.
Boccon-Gibod L, Bertaccini A, Bono AV, et al: Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract 2003;57:187-194.
25.
Gerber GS, Thisted RA, Chodak GW, et al: Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997;32:385-390.
26.
Loeb S, Smith ND, Roehl KA, et al: Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007;69:1170-1175.
27.
Lawton CA, DeSilvio M, Roach M 3rd, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007;69:646-655.
28.
Raina R, Agarwal A, Goyal KK: Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. Urology 2003;62:1103-1108.
29.
Bolla M, Van Tienhoven G, Warde P, et al: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066-1073.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.